Transient Receptor Potential Melastatin 4 (TRPM4) is associated with an immuno-stimulatory TME and better prognosis in BLCA
High TRPM4 shapes a more immuno-stimulatory tumor microenvironment and can not only predict the immune phenotypes but also predict the clinical phenotypes in BLCA. High TRPM4 predicts better prognosis. TRPM4 is a potential biomarker in the future for identifying the immunogenicity and immune-therapy probability of BLCA.
Authors
- Zixu Chen (ORCID: https://orcid.org/0000-0002-7305-9711)
- Yunxin Li (ORCID: https://orcid.org/0000-0003-4819-2489)
- Lianbo Yu (ORCID: https://orcid.org/0000-0002-2025-2585)
- Yuyue Zhang (ORCID: https://orcid.org/0000-0003-4191-3730)
- Xuerui Chen
- Hualin Wang (ORCID: https://orcid.org/0000-0002-2672-9209)
- Yuan Liu (ORCID: https://orcid.org/0000-0003-4887-907X)
- Yao Geng (ORCID: https://orcid.org/0000-0002-7330-1803)
- Zhuang Zhu
- Yurong Da
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1007/s12672-025-04080-z
- Primary Topic
- Ion Channels and Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00